繁體
简体中文
繁體中文

偉能集團 01608.HK

等待開盤 08-14 09:00:00

0.239

-0.036

-13.09%

华盛通華盛通
立即下載
  • 最 高0.280
  • 今 開0.275
  • 成交量 173.30万股
  • 最 低 0.239
  • 昨 收 0.275
  • 總市值 15.97亿
  • 52周最高 0.500
  • 市盈率 --
  • 換手率 0.00%
  • 52周最低 0.141
  • 委 比 51.47%
  • 總股本 66.83亿
  • 歷史最高 0.400
  • 量 比 1.43
  • 振 幅 14.91%
  • 歷史最低 0.141
  • 每 手 1000
  • 風險率 0.06%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • VivoPower To Purchase Initial US$100 Million of Ripple Shares, Effectively Buying XRP at an Implied US$0.47 Per Token

    VivoPower International PLC will acquire $100 million of privately held Ripple Labs shares, becoming the first U.S.-listed company to provide exposure to both Ripple shares and XRP tokens. This strategic move aims to average down the acquisition price per XRP, offering potential upside for shareholders. The acquisition could accrete $5.15 per share to VivoPower for every $10 million of Ripple shares purchased. Ripple holds 41 billion XRP tokens, ...

    08-08 13:30

  • 伟能集团(01608.HK)8月6日收盘涨9.09%,主力资金净流入1.28万港元

    证券之星消息,截至2025年8月6日收盘,伟能集团(01608.HK)报收于0.3港元,上涨9.09%,成交量313.1万股,成交额92.81万港元。

    08-06 17:53

  • 伟能集团(01608.HK)发盈喜 预计中期股东应占合并溢利约2000万港元 同比扭亏为盈

    伟能集团(01608.HK)发布公告,预期截至2025年6月30日止六个月录得未经审核公司拥有人应占合并溢利约2000万港元,2024年同期录得公司拥有人应占合并亏损约1.39亿港元。

    08-06 12:50

  • 【盈喜】伟能集团(01608.HK)料中期扭亏为盈 溢利2000万港元

    【财华社讯】伟能集团(01608.HK)公布,预期截至2025年6月30日止六个月公司拥有人应占合并溢利约2000万港元,2024年同期录得公司拥有人应占合并亏...

    08-06 12:28

  • scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025

    scPharmaceuticals Inc. has scheduled a conference call and webcast on August 7, 2025, at 4:30 p.m. ET, to discuss its second-quarter 2025 financial results and provide a business update. Participants can join via phone or webcast using the provided links and passcode 4965353. The live webcast and replay will also be accessible on the company’s website. scPharmaceuticals, headquartered in Burlington, MA, focuses on cardiorenal care innovations.

    07-31 20:01

  • VivoPower Receives NASDAQ Notification Regarding Commencement of Options Trading 

    VivoPower International PLC(纳斯达克股票代码:VVPR)宣布,纳斯达克期权市场将于2025年7月25日开始上市VVPR标准化期权。此举反映机构和散户投资者对VVPR股票兴趣的增加。期权交易将包括多种到期日和行权价,通过期权清算公司(OCC)清算,并遵循纳斯达克和OCC的标准规则。VVPR期权上市标志着公司资本市场和投资者可及性的重大扩展,为投资者提供更多风险管理工具,提升交易效率和流动性。VivoPower正转型为全球首家专注于XRP的数字资产企业,致力于通过持有和管理XRP资产,支持XRP Ledger(XRPL)的增长及DeFi和现实区块链应用的发展。公司成立于2014年,业务遍及全球,旗下拥有专注于电动解决方案的Tembo和专注可再生能源应用的Caret Digital两大部门。

    07-24 13:15

  • VivoPower Strengthens Balance Sheet, Further Reduces Debt by US$7.5 Million

    VivoPower International PLC has reduced its liabilities by exchanging outstanding monies with selected lenders and suppliers for ordinary shares, subject to lock-up conditions. Directors also opted to receive shares instead of certain fees, with limited shares tradable to cover taxes. These measures improved the balance sheet by $7.5 million. The company is on track to retire its debts, including the AWN shareholder loan, and remains committed to...

    07-22 12:30

  • Ripple与SEC缠斗终落幕 XRP迎来新起点?

    Ripple与美国证券交易委员会(SEC)的法律诉讼最终落下帷幕,双方分别撤回上诉,结束了长达五年的纠纷。法院裁决明确XRP的程序化交易不属于证券范畴,同时Ripple需支付1.25亿美元罚款并继续运营。这一裁决为加密货币的法律定性提供了重要先例,结束了行业的监管不确定。 Ripple在诉讼期间持续技术升级,推动跨链合作、稳定币生态和真实资产代币化,并积极拓展中东市场,与迪拜政府合作推进房地产代币化项目。XRP价格虽在2-2.6美元区间波动,但市场预期其长期上涨潜力。这场诉讼不仅改变了Ripple的命运,也重塑了加密行业的监管认知。

    07-02 02:39

  • VivoPower Believes It Meets Nasdaq Equity Requirement Following Reg S Investment

    VivoPower International PLC announced that, as of May 31, 2024, it believes it has regained compliance with Nasdaq's Listing Rule 5550(b)(1), with a pro forma stockholders' equity of approximately US$20 million, meeting the minimum requirement. This follows a binding close of the first phase of a private placement totaling US$60.5 million in gross proceeds, part of a larger US$121 million investment led by Prince Abdulaziz bin Turki bin Talal Al ...

    06-26 19:55

  • 伟能集团(01608.HK)6月10日收盘跌3.45%

    证券之星消息,截至2025年6月10日收盘,伟能集团(01608.HK)报收于0.28港元,下跌3.45%,成交量13.7万股,成交额3.96万港元。

    06-10 18:02